Saturday, August 22, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Rush to Establish Content-Authenticity Standards Amid Leadership Shakeups and Sustained Capex
Within days of each other in mid-August 2026, Google, Anthropic, and Spotify moved to formalize AI content watermarking and labeling policies, signaling an industry-wide push toward self-governed provenance standards as generative AI output floods consumer platforms. The shift coincides with executive turnover at OpenAI (Brad Lightcap's departure) and Meta's public AI manifesto, all set against continued heavy AI infrastructure capital expenditure and finance-sector moves (e.g., Wall Street paying for algorithmic edges on social signals) that underscore AI's deepening entanglement with capital markets.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,977
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,977 facts checked against source5,242 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Earnings callNasdaq· November 28, 2025

Bristol-Myers (BMY) Earnings Call Transcript

View original at nasdaq.com
Bristol-Myers (BMY) Earnings Call Transcript Image source: The Motley Fool. Date Oct. 30, 2025 at 4:06 p.m…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Reblozyl annualizing over $2B in revenue

    80% confidence

  • Operating expenses expected at ~$16.5B in 2025, representing over $1B net savings versus 2024

    80% confidence

  • ADEPT-2 study data for Cobenfy in Alzheimer's disease psychosis expected end of 2025

    80% confidence

  • Sotyktu direct-to-patient program offers >80% discount effective January 1

    80% confidence

  • Anti-tau antibody Phase II data expected in 2027

    80% confidence

  • Breyanzi annualizing over $1B in revenue

    80% confidence

  • All 3 milvexian Phase III trials (AFib, ACS, SSP) now expected to read out in 2026

    80% confidence

  • US manufacturing hub opened for radiopharmaceutical therapies with 3-day delivery to patients

    80% confidence

  • Pumitamig early data to be presented at San Antonio Breast Cancer Symposium in December 2025

    80% confidence

  • Sotyktu pivotal studies for autism spectrum irritability to initiate in 2026

    80% confidence

  • Camzyos annualizing over $1B in revenue

    80% confidence

  • Discussions with FDA and multiple regulators for accelerated/conditional approval of iberdomide

    80% confidence

  • Non-GAAP EPS guidance for 2025: $6.40-$6.60 with midpoint unchanged but range narrowed

    80% confidence

  • Milvexian targeting approximately 40% of AFib patients unsuitable for Factor Xa anticoagulants

    80% confidence

  • Discussions with administration on Medicare/Medicaid pricing are frequent and constructive

    80% confidence

  • By end of decade, potential for 10 new medicines and ≥30 life cycle management opportunities

    80% confidence

  • Strategic productivity initiative targeting $2B savings by 2027 with clear line of sight confirmed

    80% confidence

  • Full-year 2025 revenue guidance raised to $47.5B-$48B, representing $750M increase at midpoint

    80% confidence

  • Cobenfy has achieved virtually 100% access in Medicare/Medicaid in US

    80% confidence

  • No plan to revisit Eliquis IRA negotiation, price effective January 1, 2026

    80% confidence

  • Eliquis direct-to-patient program offers >40% less than list price

    80% confidence

  • Legacy portfolio expected to decline 15%-17% in 2025

    80% confidence

  • Cobenfy achieving over 2,400 weekly TRxs

    80% confidence

  • Iberdomide PFS data expected in 2026

    80% confidence

  • Debt paydown target of $10B by first half 2026, with $6.7B already repaid

    80% confidence

  • 2 additional Cobenfy Alzheimer's disease psychosis studies expected in 2026, need 2 of 3 positive for approval

    80% confidence

  • Next 12-24 months will see data for 7 new molecular entities and 7 life cycle management opportunities

    80% confidence

  • Opdivo + Qvantig expected to achieve high single-digit to low double-digit growth full year (raised guidance)

    80% confidence

Cited in these Via News reports